The U.S. Food and Drug Administration has approved a new drug that, for the first time, treats the neurological symptoms of Type 3 Gaucher disease (GD3), a rare inherited disorder that progressively damages the brain and nervous system.

The medication, Infilbray (venglustat), was approved on November 18, 2026 for adults and children weighing at least 15 kilograms (about 33 pounds), according to an FDA press release. It is the first therapy cleared for the neurological manifestations of GD3, a condition that affects roughly one in 100,000 to 200,000 people worldwide, though exact prevalence varies by population.

GD3 is caused by a genetic deficiency in an enzyme needed to break down fatty substances called glucosphingolipids. In Type 3 disease, these substances accumulate not only in organs and tissues but also in the brain, leading to problems with balance, coordination, speech, memory, and thinking. These symptoms can worsen over time and significantly impair quality of life. Unlike the more common Type 1 Gaucher disease, which does not involve the central nervous system, GD3 directly affects the brain.

Infilbray works as a glucosylceramide synthase inhibitor. The FDA noted that the drug is able to cross the blood-brain barrier, a protective layer that normally blocks many substances from entering the brain, allowing it to reduce the buildup of harmful materials at their source.

“For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” said Acting FDA Commissioner Kyle Diamantas in the announcement.

The approval was supported by a randomized, double-blind, multicenter clinical trial involving 43 patients aged 12 and older with GD3 who had previously been treated with enzyme replacement therapy and had achieved systemic disease stabilization. Participants received either Infilbray orally once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks.

Researchers evaluated treatment effectiveness using two assessments that capture neurological symptoms central to daily life in GD3 patients, including measures of ataxia (loss of muscle control and coordination) and cognitive function. At week 52, patients taking Infilbray showed improvement on a combined measure compared to those continuing enzyme replacement therapy for non-neurologic symptoms.

The most frequently reported side effects included gastrointestinal symptoms and adverse effects on mood. The FDA also reported serious psychiatric risks, including suicidal ideation and behavior. Animal studies suggested potential risks of clouding of vision in younger patients and adverse effects on fetal development if taken during pregnancy.

Infilbray was granted Orphan Drug designation, which provides incentives for developing treatments for rare diseases, as well as Priority Review, which speeds the FDA's evaluation process. The drug is manufactured by Genzyme Corporation, a Sanofi company.

For university students studying medicine, pharmacology, or public health, the approval illustrates how targeted drug design — specifically engineering a molecule to cross the blood-brain barrier — can address previously untreatable aspects of rare genetic diseases. It also highlights the role of regulatory incentives like Orphan Drug status in encouraging pharmaceutical development for small patient populations.

Patients and caregivers seeking more information about side effects can consult the drug's official labeling, which the FDA has made available alongside the approval announcement.